$2500 | Single User
$5000 | Site License
$7500 | Enterprise License

Non Alcoholic Fatty Liver Disease (NAFLD) Global Clinical Trials Review, H2, 2015
[Lowest Price Guaranteed: $2,500]

Published by Global Data: 16 Dec 2015 | 17771 | In Stock
Related Topics: Clinical Trials

Introduction

Non Alcoholic Fatty Liver Disease (NAFLD) Global Clinical Trials Review, H2, 2015

Summary

GlobalData's clinical trial report, “Non Alcoholic Fatty Liver Disease (NAFLD) Global Clinical Trials Review, H2, 2015" provides an overview of Non Alcoholic Fatty Liver Disease (NAFLD) clinical trials scenario. This report provides top line data relating to the clinical trials on Non Alcoholic Fatty Liver Disease (NAFLD). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape

- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

- The Report provides enrollment trends for the past five years

- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment

- Helps in identifying prominent locations for conducting clinical trials which saves time and cost

- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

- Supports understanding of trials count and enrollment trends by country in global therapeutics market

- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents
for Non Alcoholic Fatty Liver Disease (NAFLD) Global Clinical Trials Review, H2, 2015

  • Table of Contents

    Table of Contents 2

    List of Tables 3

    List of Figures 4

    Report Guidance 5

    Clinical Trials by Region 6

    Clinical Trials and Average Enrollment by Country 7

    Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10

    Top Five Countries Contributing to Clinical Trials in Europe 11

    Top Countries Contributing to Clinical Trials in North America 12

    Top Countries Contributing to Clinical Trials in Middle East and Africa 13

    Top Countries Contributing to Clinical Trials in Central and South America 14

    Clinical Trials by G7 Countries: Proportion of Non Alcoholic Fatty Liver Disease (NAFLD) to Gastrointestinal Clinical Trials 15

    Clinical Trials by Phase in G7 Countries 17

    Clinical Trials in G7 Countries by Trial Status 18

    Clinical Trials by E7 Countries: Proportion of Non Alcoholic Fatty Liver Disease (NAFLD) to Gastrointestinal Clinical Trials 19

    Clinical Trials by Phase in E7 Countries 20

    Clinical Trials in E7 Countries by Trial Status 21

    Clinical Trials by Phase 22

    In Progress Trials by Phase 23

    Clinical Trials by Trial Status 24

    Clinical Trials by End Point Status 25

    Subjects Recruited Over a Period of Time 26

    Clinical Trials by Sponsor Type 27

    Prominent Sponsors 28

    Top Companies Participating in Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials 29

    Prominent Drugs 31

    Latest Clinical Trials News on Non Alcoholic Fatty Liver Disease (NAFLD) 32

    Nov 16, 2015: NIDDK Provides Additional Data From CyNCh Study Evaluating RP103 in Pediatric NASH at AASLD 32

    Oct 08, 2015: NuSirt Biopharma Plans Clinical Trial in Non-Alcoholic Fatty Liver Disease 32

    Clinical Trial Profile Snapshots 34

    Appendix 194

    Abbreviations 194

    Definitions 194

    Research Methodology 195

    Secondary Research 195

    About GlobalData 196

    Contact Us 196

    Disclaimer 196

    Source 197

List Of Tables
in Non Alcoholic Fatty Liver Disease (NAFLD) Global Clinical Trials Review, H2, 2015

List of Tables

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials by Region, 2015* 6

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 8

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2015* 10

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Europe, Top Five Countries, 2015* 11

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, North America, Top Countries, 2015* 12

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2015* 13

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Central and South America, Top Countries, 2015* 14

Proportion of Non Alcoholic Fatty Liver Disease (NAFLD) to Gastrointestinal Clinical Trials, G7 Countries (%), 2015* 16

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 17

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 18

Proportion of Non Alcoholic Fatty Liver Disease (NAFLD) to Gastrointestinal Clinical Trials, E7 Countries (%), 2015* 19

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 20

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 21

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials by Phase, 2015* 22

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials In Progress by Phase 2015* 23

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials by Trial Status, 2015* 24

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Global, by End Point Status, 2015* 25

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 26

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015* 27

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 28

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 30

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 31

List Of Figures, Charts and Diagrams
in Non Alcoholic Fatty Liver Disease (NAFLD) Global Clinical Trials Review, H2, 2015

List of Figures

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials by Region (%), 2015* 6

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 7

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2015* 10

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2015* 11

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, North America, Top Countries (%), 2015* 12

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2015* 13

Proportion of Non Alcoholic Fatty Liver Disease (NAFLD) to Gastrointestinal Clinical Trials, G7 Countries (%), 2015* 15

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 17

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 18

Proportion of Non Alcoholic Fatty Liver Disease (NAFLD) to Gastrointestinal Clinical Trials, E7 Countries (%), 2015* 19

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 20

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 21

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials by Phase (%), 2015* 22

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials In Progress by Phase, 2015* 23

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials by Trial Status, 2015* 24

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Global, by End Point Status, 2015* 25

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 26

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015* 27

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 28

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 29

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 31

GlobalData Methodology 195

Additional Details

Publisher

Global Data

Publisher Information

Reference

17771 | GDHC3082CTIDB

Number of Pages

197

Report Format

PDF

Global Data Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Alcoholic Hepatitis Global Clinical Trials Review, H2, 2018
Alcoholic Hepatitis Global Clinical Trials Review, H2, 2018SummaryGlobalData's clinical trial report...
25 Oct 2018 by Global Data USD $2,500 More Info
EpiCast Report: Non-Alcoholic Steatohepatitis - Epidemiology Forecast to 2025
EpiCast Report: Non-Alcoholic Steatohepatitis - Epidemiology Forecast to 2025SummaryNon-alcoholic st...
01 Dec 2016 by Global Data USD $3,995 More Info
Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H2, 2016
Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical tr...
30 Nov 2016 by Global Data USD $2,500 More Info
Alcoholic Hepatitis Global Clinical Trials Review, H2, 2016
Alcoholic Hepatitis Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial report...
31 Oct 2016 by Global Data USD $2,500 More Info
Non Alcoholic Fatty Liver Disease (NAFLD) Global Clinical Trials Review, H2, 2016
Non Alcoholic Fatty Liver Disease (NAFLD) Global Clinical Trials Review, H2, 2016SummaryGlobalData's...
31 Oct 2016 by Global Data USD $2,500 More Info
Alcoholic Hepatitis Global Clinical Trials Review, H2, 2015
Alcoholic Hepatitis Global Clinical Trials Review, H2, 2015SummaryGlobalData's clinical trial report...
16 Dec 2015 by Global Data USD $2,500 More Info
Non-Alcoholic SteatoHepatitis (NASH): An Analysis of Disease Prevalence, Drugs in development, Regulatory guidelines and Market opportunity in Various Geographies
Within the oral mucosal cavity, the buccal region offers an attractive route of administration for s...
01 Dec 2015 by MP Advisors USD $3,500 More Info
Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H2, 2015
Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H2, 2015SummaryGlobalData's clinical tr...
30 Nov 2015 by Global Data USD $2,500 More Info
North America Starter Cultures Market by Application (Alcoholic Beverages, and Non-Alcoholic Beverages), by Type (Yeast, Bacteria, and Molds), by Geography (U.S., Canada, and Mexico) - Analysis and Forecast to 2019
The North American starter cultures market is estimated to grow at a CAGR of 6.7% from 2014 to 2019....
25 May 2015 by MicroMarketMonitor USD $2,650 More Info
North America Starter Cultures Market by Application (Alcoholic Beverages, and Non-Alcoholic Beverages), by Type (Yeast, Bacteria, and Molds), by Geography (U.S., Canada, and Mexico) - Analysis and Forecast to 2019
The North American starter cultures market is estimated to grow at a CAGR of 6.7% from 2014 to 2019....
25 May 2015 by MarketsandMarkets USD $2,650 More Info

This report is published by Global Data

Download Free Report Summary PDF

Non Alcoholic Fatty Liver Disease (NAFLD) Global Clinical Trials Review, H2, 2015 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...